Patient-Derived Gastric Cancer Assembloids: Advancing Tumor Microenvironment Modeling

Study Background and Research Question

Gastric cancer remains a leading cause of cancer-related mortality worldwide, with a five-year survival rate below 10% for advanced cases [paper|https://doi.org/10.3390/cancers17142287]. The heterogeneity of gastric tumors and their complex microenvironments—comprising tumor epithelial cells and diverse stromal components—underpin substantial variability in treatment response and prognosis. Conventional three-dimensional (3D) in vitro models, such as organoids, capture some tumor-specific features but often lack the full cellular diversity and context that influence therapeutic outcomes. Recognizing these limitations, Shapira-Netanelov et al. sought to develop an in vitro model that more faithfully recapitulates the patient-specific tumor microenvironment, enabling more predictive preclinical testing and mechanistic studies [paper|https://doi.org/10.3390/cancers17142287].

Key Innovation from the Reference Study

The central innovation of this research lies in the creation of assembloids—integrated 3D structures combining patient-derived gastric tumor organoids with matched stromal cell subpopulations (including fibroblasts, mesenchymal stem cells, and endothelial cells) isolated from the same tumor tissue. This assembloid approach preserves the autologous cellular landscape and allows the study of tumor–stroma crosstalk and its impact on gene expression, biomarker profiles, and drug responsiveness. The inclusion of multiple stromal cell types, rather than generic or unmatched stromal cells, provides a closer physiological approximation to the primary tumor niche, supporting a more nuanced investigation of personalized drug responses and resistance mechanisms [paper|https://doi.org/10.3390/cancers17142287].

Methods and Experimental Design Insights

Tumor specimens from gastric cancer patients were enzymatically dissociated to yield single-cell suspensions. These cells were expanded in lineage-specific media to establish pure populations of epithelial organoids, mesenchymal stem cells, fibroblasts, and endothelial cells. The key methodological step was the co-culture of these autologous populations in an optimized assembloid medium, supporting the survival and proliferation of each cell type [paper|https://doi.org/10.3390/cancers17142287]. Tumor–stroma assembloids were characterized using:

• Immunofluorescence staining to confirm expression of epithelial and stromal markers, verifying the presence and spatial organization of diverse cell types.
• RNA sequencing to assess transcriptomic profiles and gene expression dynamics in response to co-culture.
• Cell viability and drug response assays to evaluate the sensitivity of assembloids versus monocultures to various chemotherapeutic and targeted agents.

This comprehensive approach enabled the dissection of cell–cell interactions and their influence on therapeutic efficacy.

Core Findings and Why They Matter

The study demonstrated that assembloids exhibit a cellular and molecular landscape closely resembling that of primary gastric tumors. The presence of matched stromal subpopulations significantly altered gene expression patterns, with assembloids displaying elevated levels of inflammatory cytokines, extracellular matrix remodeling factors, and genes linked to tumor progression [paper|https://doi.org/10.3390/cancers17142287]. Importantly, drug screening revealed that the inclusion of stromal components can dramatically alter drug sensitivity. Some therapeutic agents retained efficacy across both organoid and assembloid contexts, while others lost effectiveness in the assembloid model, underscoring the stromal contribution to drug resistance and response heterogeneity. This finding has direct implications for personalized medicine, suggesting that preclinical testing in more physiologically relevant models could improve prediction of clinical outcomes and guide therapy selection [paper|https://doi.org/10.3390/cancers17142287].

Protocol Parameters

• assay | cell viability assay | variable (as per drug and cell type) | applicability: assembloids permit more accurate assessment of drug-induced cytotoxicity and proliferation compared to monocultures | paper|https://doi.org/10.3390/cancers17142287
• growth medium | tailored for organoid, mesenchymal, fibroblast, and endothelial populations | required for successful expansion and maintenance of each subpopulation | rationale: supports physiological relevance and heterogeneity | paper|https://doi.org/10.3390/cancers17142287
• drug screening | multi-agent panel (including antifolates) | assembloid and organoid comparison | applicability: enables study of resistance mechanisms and therapeutic response | paper|https://doi.org/10.3390/cancers17142287
• use of protection from methotrexate-induced growth suppression | Leucovorin Calcium, typically at 10mM working solution, stored at -20°C | supports rescue protocols in cytotoxicity assays | rationale: established workflow for evaluating folate metabolism pathway and antifolate drug resistance | workflow_recommendation|https://histone-h2a-107-122-ac-oh.com/index.php?g=Wap&m=Article&a=detail&id=16716

Comparison with Existing Internal Articles

Several internal articles discuss the application of Leucovorin Calcium as a folate analog for methotrexate (MTX) rescue in complex 3D cancer models. For instance, one article highlights Leucovorin Calcium's role in protection from methotrexate-induced growth suppression and its compatibility with assembloid systems [workflow_recommendation|https://histone-h2a-107-122-ac-oh.com/index.php?g=Wap&m=Article&a=detail&id=16826]. Another resource (see here) describes its use in antifolate drug resistance research and cell proliferation assay optimization. The reference study by Shapira-Netanelov et al. extends these concepts by integrating patient-matched stromal populations, allowing researchers to examine not only the direct effects of antifolate agents but also the influence of microenvironmental heterogeneity on drug resistance and cell viability outcomes. This aligns with ongoing efforts to use Leucovorin Calcium to modulate folate metabolism pathway responses in physiologically relevant models.

Limitations and Transferability

While the assembloid model successfully recapitulates key aspects of tumor heterogeneity and microenvironmental complexity, its transferability to other cancer types or in vivo contexts remains to be fully established. Limitations include the technical challenges of isolating and expanding autologous stromal subpopulations from limited patient tissue, and potential variability introduced by patient-specific factors. Additionally, while the model enhances physiological relevance, it does not fully replicate systemic factors present in living organisms. Further validation in larger cohorts and comparison with clinical outcomes will be essential for broader adoption [paper|https://doi.org/10.3390/cancers17142287].

Research Support Resources

For researchers aiming to replicate or extend these assembloid workflows, robust reagents are critical. Leucovorin Calcium (SKU A2489, APExBIO) is a high-purity calcium folinate suitable for protection from methotrexate-induced growth suppression in advanced 3D gastric cancer models. It is water soluble (≥15.04 mg/mL with gentle warming), recommended for short-term solution use, and should be stored at -20°C for stability [product_spec|https://www.apexbt.com/leucovorin-calcium.html]. Using validated reagents like this can support reproducibility in cell proliferation assays and investigation of the folate metabolism pathway, as demonstrated in both the cited reference and internal assembloid model literature.